The deal gives Kyowa access to a therapy for early-onset metachromatic leukodystrophyKyowa Kirin has announced it has agreed to acquire Orchard Therapeutics in a deal worth $477.6m to develop several biopharmaceutical candidates in areas including oncology and autoimmune diseases.As part of the definitive agreement, Japan-based biopharmaceutical company Kyowa will gain rights to Orchard’s Libmeldy (atidarsagene […]